Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07602257

Investigating a Personalized Approach to Anti-Platelet Therapy

RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

High Risk Bleeding Cardiovascular Diseases Embolism and Thrombosis Thrombosis Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

Location contact

Derek So, MD

PRINCIPAL_INVESTIGATOR

Poppy MacPhee, RN

CONTACT

[email protected]

613-696-7000

About this study

RAPID PREVENT is a Phase IV, single centre, physician initiated, cluster randomized pilot trial evaluating a personalized antiplatelet strategy for patients with acute coronary syndrome (ACS) with High Bleeding Risk (HBR) undergoing percutaneous coronary intervention (PCI). Monthly clusters are randomized 1:1 to either standard of care or personalized therapy guided by HBR algorithm and point of care CYP2C19 genotyping.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years old
  • Receiving PCI with stenting

Exclusion criteria

  • Inability to take ticagrelor
  • Inability to take clopidogrel
  • Not expected to survive >48hours
  • Not able to complete a buccal swab

Treatment and study plan

Genotyping guided therapy for anti-platelet management

Drug

Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin.

Participants that are not carriers of the CYP2C19 gene will receive either Plavix monotherapy or dual therapy with Plavix and Aspirin.

Primary outcomes

  1. Bleeding Events

    Time frame: Randomization to 12months

    Events that meet the BARC Type 2, 3, or 5 definitions.

Secondary outcomes

  1. MACCE Events

    Time frame: Randomization to 12months

    Composite of events of cardiovascular death, non-fatal myocardial infarction, stroke, and repeat revascularization.

  2. CV mortality

    Time frame: randomization to 12months

    Incidences of mortality associated with cardiovascular disease

  3. Non-Fatal MI

    Time frame: Randomization to 12months.

    Number of incidences of non-fatal myocardial infarctions

  4. Stroke

    Time frame: randomization to 12months

    Number of stroke events that occur

  5. Repeat revascularization

    Time frame: Randomization to 12months

    Incidences of events requiring additional unplanned revascularization procedures post randomization.

  6. Stent Thrombosis

    Time frame: Randomization to 12months.

    Incidences of identified thrombosis of previous stents.

Study contacts

Contact information is provided by the study sponsor or research team.

Poppy MacPhee, RN

CONTACT

[email protected]

613-696-7000

Sponsors and collaborators

Lead sponsor

Ottawa Heart Institute Research Corporation

Other

Registry information

Official study title

Reassessment of Anti-Platelet Therapy Using an Individualized Strategy With Pharmacogenomics to Refine Anti-Platelet Drugs in Vulnerable Patients to Eliminate Thrombotic and Bleeding Complications - A Cluster Randomized Pilot Study

Acronym: RAPID PREVENT

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
May 22, 2026
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.